الإحصائيات الأساسية
| LEI | 549300AH7DX6B7JBAP68 |
| CIK | 1600132 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Bellerophon Therapeutics, Inc.
SEC Filings (Chronological Order)
توفر هذه الصفحة قائمة كاملة ومرتبة ترتيبًا زمنيًا لتصريحات هيئة الأوراق المالية والبورصات، باستثناء تصريحات الملكية التي نقدمها في مكان آخر.
| March 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-36845 Bellerophon Therapeutics, Inc. (Exact name of registrant as specif |
|
| March 4, 2024 |
Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 1, 2024 Bellerophon Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-36845 47-3116175 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| February 14, 2024 |
BLPH / Bellerophon Therapeutics, Inc. / PERCEPTIVE ADVISORS LLC - SC 13G/A Passive Investment SC 13G/A 1 d728319dsc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Bellerophon Therapeutics, Inc. (Name of Issuer) Common Stock, $0.01 par value per share (Title of Class of Securities) 078771300 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statem |
|
| February 14, 2024 |
SC 13G/A 1 g111243sc13ga1.htm AMENDMENT NO. 1 Securities and Exchange Commission Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Bellerophon Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) 078771300 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of This Statement) Chec |
|
| February 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ¨ Defini |
|
| February 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e |
|
| January 30, 2024 |
CERTIFICATE OF DESIGNATION OF SERIES A PREFERRED STOCK OF BELLEROPHON THERAPEUTICS, INC. Exhibit 3.1 CERTIFICATE OF DESIGNATION OF SERIES A PREFERRED STOCK OF BELLEROPHON THERAPEUTICS, INC. Bellerophon Therapeutics, Inc., a Delaware corporation (“Company”), does hereby certify that the Board of Directors of the Company (“Board”) adopted the following resolution: RESOLVED, pursuant to authority conferred by the Restated Certificate of Incorporation of the Company, the Board designates, |
|
| January 30, 2024 |
Exhibit 10.1 Bellerophon Therapeutics, Inc. Series A Non-Convertible Preferred Stock SUBSCRIPTION AND INVESTMENT REPRESENTATION AGREEMENT THIS AGREEMENT, dated as of January 25, 2024, is by and between Bellerophon Therapeutics, Inc., a Delaware corporation (the “Company”), and the undersigned subscriber (the “Subscriber”). In consideration of the mutual promises contained herein, and other good, v |
|
| January 30, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 25, 2024 Bellerophon Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-36845 47-3116175 (State or Other Jurisdiction of Incorporation) (Commis |
|
| January 26, 2024 |
BLPH / Bellerophon Therapeutics, Inc. / Lepercq De Neuflize Asset Management LLC Passive Investment SC 13G 1 bti13g-121823.htm SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G (RULE 13d - 102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO 13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2(b) (Amendment No. )* Bellerophon Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) 078771300* (CUSIP |
|
| January 22, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 22, 2024 Bellerophon Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-36845 47-3116175 (State or Other Jurisdiction of Incorporation) (Commis |
|
| January 10, 2024 |
Other Events, Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 10, 2024 Bellerophon Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-36845 47-3116175 (State or Other Jurisdiction of Incorporation) (Commis |
|
| January 3, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ¨ Defini |
|
| December 12, 2023 |
Other Events, Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): December 11, 2023 Bellerophon Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-36845 47-3116175 (State or Other Jurisdiction of Incorporation) (Commi |
|
| November 21, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 15, 2023 Bellerophon Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-36845 47-3116175 (State or Other Jurisdiction of Incorporation) (Commi |
|
| November 14, 2023 |
Exhibit 10.3 August 3, 2023 Parag S. Shah Re: Separation Agreement Dear Parag: The purpose of this letter agreement (this “Agreement”) is to set forth the terms of your transition and separation from Bellerophon Therapeutics, Inc. (the “Company”). You may take up to forty-five (45) calendar days from the date you receive this Agreement to review it and decide whether to sign it. If you sign this A |
|
| November 14, 2023 |
Exhibit 10.2 August 3, 2023 Peter P. Fernandes Re: Separation Agreement Dear Peter: The purpose of this letter agreement (this “Agreement”) is to set forth the terms of your transition and separation from Bellerophon Therapeutics, Inc. (the “Company”). You may take up to forty-five (45) calendar days from the date you receive this Agreement to review it and decide whether to sign it. If you sign t |
|
| November 14, 2023 |
Exhibit 10.1 July 13, 2023 Martin P. Dekker Re: Separation Agreement Dear Martin: The purpose of this letter agreement (this “Agreement”) is to set forth the terms of your transition and separation from Bellerophon Therapeutics, Inc. (the “Company”). You may take up to forty-five (45) calendar days from the date you receive this Agreement to review it and decide whether to sign it. If you sign thi |
|
| November 14, 2023 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Numbe |
|
| November 6, 2023 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. 1) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitt |
|
| October 27, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a party other than the Registrant ¨ Check the appropriate box: x Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e |
|
| October 18, 2023 |
SC 13D/A 1 13DA-4.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No.4)* Bellerophon Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) 078771300 (CUSIP Number) Name: Theodore Wang c/o Puissance Capital Management LP 45 E 85th St, 5A New York, New Yo |
|
| October 17, 2023 |
SC 13D/A 1 13DA-4.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No.4)* Bellerophon Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) 078771300 (CUSIP Number) Name: Theodore Wang c/o Puissance Capital Management LP 45 E 85th St, 5A New York, New Yo |
|
| October 16, 2023 |
As filed with the Securities and Exchange Commission on October 16, 2023 As filed with the Securities and Exchange Commission on October 16, 2023 Registration No. |
|
| October 16, 2023 |
As filed with the Securities and Exchange Commission on October 16, 2023 As filed with the Securities and Exchange Commission on October 16, 2023 Registration No. |
|
| October 16, 2023 |
As filed with the Securities and Exchange Commission on October 16, 2023 As filed with the Securities and Exchange Commission on October 16, 2023 Registration No. |
|
| October 16, 2023 |
As filed with the Securities and Exchange Commission on October 16, 2023 As filed with the Securities and Exchange Commission on October 16, 2023 Registration No. |
|
| October 16, 2023 |
As filed with the Securities and Exchange Commission on October 16, 2023 As filed with the Securities and Exchange Commission on October 16, 2023 Registration No. |
|
| October 16, 2023 |
As filed with the Securities and Exchange Commission on October 16, 2023 As filed with the Securities and Exchange Commission on October 16, 2023 Registration No. |
|
| October 16, 2023 |
BELLEROPHON THERAPEUTICS, INC. 20 Independence Boulevard, Suite 402 Warren, New Jersey 07059 (908) 574-4770 October 16, 2023 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F. Street N.E. Washington, D.C. 20549 Re: Bellerophon Therapeutics, Inc. – Request for Withdrawal of Registration Statement on Form S-3 (File No. 333-272359) Ladies and Gentlemen: Pursuant to Ru |
|
| October 16, 2023 |
As filed with the Securities and Exchange Commission on October 16, 2023 As filed with the Securities and Exchange Commission on October 16, 2023 Registration No. |
|
| October 16, 2023 |
As filed with the Securities and Exchange Commission on October 16, 2023 As filed with the Securities and Exchange Commission on October 16, 2023 Registration No. |
|
| October 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): October 12, 2023 Bellerophon Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-36845 47-3116175 (State or Other Jurisdiction of Incorporation) (Commis |
|
| October 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): October 12, 2023 Bellerophon Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-36845 47-3116175 (State or Other Jurisdiction of Incorporation) (Commis |
|
| October 13, 2023 |
Plan of Liquidation and Dissolution of Bellerophon Therapeutics, Inc. Exhibit 2.1 PLAN OF LIQUIDATION AND DISSOLUTION OF BELLEROPHON THERAPEUTICS, INC. This Plan of Liquidation and Dissolution (the “Plan”) is intended to accomplish the complete liquidation and dissolution of BELLEROPHON THERAPEUTICS, INC., a Delaware corporation (such corporation or a successor entity, the “Company”), in accordance with Section 281(b) of the General Corporation Law of the State of D |
|
| August 14, 2023 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001 |
|
| August 7, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 3, 2023 Bellerophon Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-36845 47-3116175 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| July 24, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July 19, 2023 Bellerophon Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-36845 47-3116175 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| July 20, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July 13, 2023 Bellerophon Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-36845 47-3116175 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| July 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July 10, 2023 Bellerophon Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-36845 47-3116175 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| June 29, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 24, 2023 Bellerophon Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-36845 47-3116175 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| June 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 7, 2023 Bellerophon Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-36845 47-3116175 (State or Other Jurisdiction of Incorporation) (Commission |
|
| June 9, 2023 |
Amended and Restated 2015 Equity Incentive Plan. Exhibit 10.1 Appendix A BELLEROPHON THERAPEUTICS LLC AMENDED AND RESTATED 2015 EQUITY INCENTIVE PLAN (amended and restated as of June 7, 2023) 1. Purpose The purpose of this 2015 Equity Incentive Plan (the “Plan”) of Bellerophon Therapeutics LLC, a Delaware limited liability company (the “Company”), is to advance the interests of the Company’s shareholders by enhancing the Company’s ability to att |
|
| June 8, 2023 |
BELLEROPHON THERAPEUTICS, Inc. 20 Independence Boulevard, Suite 402 Warren, New Jersey 07059 BELLEROPHON THERAPEUTICS, Inc. 20 Independence Boulevard, Suite 402 Warren, New Jersey 07059 June 8, 2023 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Mr. Jason Drory Re: Bellerophon Therapeutics, Inc. Registration Statement on Form S-3 Filed June 2, 2024 File No. 333- 272359 (the “Registration Statement”) Ac |
|
| June 8, 2023 |
SC 13D/A 1 13DA.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No.3)* Bellerophon Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) 078771300 (CUSIP Number) Name: Theodore Wang c/o Puissance Capital Management LP 45 E 85th St, 5A New York, New York |
|
| June 7, 2023 |
Calculation of Filing Fee Table Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) Bellerophon Therapeutics, Inc. |
|
| June 7, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Bellerophon Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 47-3116175 (State or other jurisdiction of incorporation or organization) (IRS Employer Identification No.) 20 Independence Boulevard, Suite 402 Warren, New Jersey 0705 |
|
| June 5, 2023 |
Exhibit 99.1 Bellerophon Announces Top-Line Data from Phase 3 REBUILD Clinical Trial of INOpulse® for Treatment of Fibrotic Interstitial Lung Disease - Trial did not meet its primary endpoint related to the change in moderate to vigorous physical activity - INOpulse® was safe and well-tolerated, consistent with the overall safety profile demonstrated in Phase 2 and other INOpulse® programs in PH-C |
|
| June 5, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 5, 2023 Bellerophon Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-36845 47-3116175 (State or Other Jurisdiction of Incorporation) (Commission |
|
| June 5, 2023 |
Conference Call I June 5, 2023 Bellerophon Therapeutics Exhibit 99.2 Conference Call I June 5, 2023 Bellerophon Therapeutics Bellerophon Therapeutics Overview | June 2023 2 Forward Looking Statements This presentation contains forward - looking statements that involve substantial risks and uncertainties . All statements, other than statements of historical facts, contained in this presentation, including statements regarding our strategy, future operat |
|
| June 2, 2023 |
Exhibit 4.4 BELLEROPHON THERAPEUTICS, INC. Issuer AND [ ] Trustee INDENTURE Dated as of [ ] Senior Debt Securities CROSS-REFERENCE TABLE (1) Section of Trust Indenture Act of 1939, as Amended Section of Indenture 310(a). 7.09 310(b). 7.08 7.10 310(c). Inapplicable 311(a). 7.13(a) 311(b). 7.13(b) 311(c). Inapplicable 312(a) 5.02(a) 312(b). 5.02(b) 312(c). 5.02(c) 313(a). 5.04(a) 313(b). 5.04(a) 31 |
|
| June 2, 2023 |
Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Bellerophon Therapeutics, Inc. |
|
| June 2, 2023 |
Form of Subordinated Indenture Exhibit 4.5 BELLEROPHON THERAPEUTICS, INC. Issuer AND [ ] Trustee INDENTURE Dated as of [ ] Subordinated Debt Securities CROSS-REFERENCE TABLE (1) Section of Trust Indenture Act of 1939, as Amended Section of Indenture 310(a). 7.09 310(b). 7.08 7.10 310(c). Inapplicable 311(a). 7.13(a) 311(b). 7.13(b) 311(c). Inapplicable 312(a). 5.02(a) 312(b). 5.02(b) 312(c). 5.02(c) 313(a). 5.04(a) 313(b). 5.04 |
|
| June 2, 2023 |
As filed with the Securities and Exchange Commission on June 2, 2023 As filed with the Securities and Exchange Commission on June 2, 2023 Registration No. |
|
| June 2, 2023 |
Form of Specimen Stock Certificate Exhibit 4.1 THIS CERTIFIES THAT is the owner of CUSIP DATED COUNTERSIGNED AND REGISTERED: COMPUTERSHARE TRUST COMPANY, N.A. TRANSFER AGENT AND REGISTRAR, FULLY-PAID AND NON-ASSESSABLE SHARES OF COMMON STOCK OF Bellerophon Therapeutics, Inc. (hereinafter called the “Company”), transferable on the books of the Company in person or by duly authorized attorney, upon surrender of this Certificate prope |
|
| May 31, 2023 |
Up to $40,000,000 Common Stock Filed Pursuant to Rule 424(b)(5) Registration No. 333-239473 Prospectus Supplement (To Prospectus Supplements dated July 17, 2020 and January 19, 2023 and Prospectus dated July 2, 2020) Up to $40,000,000 Common Stock We previously entered into an Open Market Sale AgreementSM, dated July 17, 2020, or the sales agreement, with Jefferies LLC, or Jefferies, relating to the sale of shares of our common |
|
| May 25, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 Amendment No.: 0* Name of Issuer: Bellerophon Therapeutics, Inc. Title of Class of Securities: Common Stock CUSIP Number: 078771300 Date of Event Which Requires Filing of this Statement: 5/15/2023 Check the appropriate box to designate the rule pursuant to which this Sched |
|
| May 22, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No.2)* Bellerophon Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) 078771300 (CUSIP Number) Name: Theodore Wang c/o Puissance Capital Management LP 45 E 85th St, 5A New York, New York 10028 Telephone Num |
|
| May 15, 2023 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 00 |
|
| May 15, 2023 |
Exhibit 10.1 TECHNOLOGY LICENSE AGREEMENT This TECHNOLOGY LICENSE AGREEMENT (this “Agreement”) is made as of January 4, 2023 (the “Effective Date”) by and between Baylor Biosciences, Inc., a company organized and existing under the laws of the People’s Republic of China (“Baylor”), Bellerophon Pulse Technologies LLC, a limited liability company organized and existing under the laws of Delaware, th |
|
| May 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 15, 2023 Bellerophon Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-36845 47-3116175 (State or Other Jurisdiction of Incorporation) (Commission |
|
| May 15, 2023 |
Bellerophon Provides Clinical Program Update and Reports First Quarter 2023 Financial Results Exhibit 99.1 Bellerophon Provides Clinical Program Update and Reports First Quarter 2023 Financial Results - Last Patient Completed Blinded Treatment in REBUILD Phase 3 Trial for INOpulse®; Pivotal Top-line Data Expected in Mid-2023 WARREN, N.J., May 15, 2023 – Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company focused on develo |
|
| May 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 11, 2023 Bellerophon Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-36845 47-3116175 (State or Other Jurisdiction of Incorporation) (Commission |
|
| May 11, 2023 |
Exhibit 99.1 Bellerophon Therapeutics Announces Last Patient Has Completed Blinded Treatment in Phase 3 REBUILD Study for INOpulse® in Fibrotic Interstitial Lung Disease Pivotal top-line data readout expected in mid-2023 WARREN, N.J., May 11, 2023 – Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company focused on developing treatme |
|
| May 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 5, 2023 Bellerophon Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-36845 47-3116175 (State or Other Jurisdiction of Incorporation) (Commission |
|
| May 5, 2023 |
Exhibit 10.1 May 4, 2023 Nick Laccona Re: Separation Agreement Dear Nick: The purpose of this letter agreement (this “Agreement”) is to set forth the terms of your separation from Bellerophon Therapeutics (the “Company”). Payment of the Separation Benefits described below is contingent on your agreement to and compliance with the terms of this Agreement. 1. Separation of Employment. As of May 5, 2 |
|
| May 5, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 4, 2023 Bellerophon Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-36845 47-3116175 (State or Other Jurisdiction of Incorporation) (Commission |
|
| April 28, 2023 |
DEFA14A 1 blph-20230428xdefa14a.htm DEFA14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant [X] Filed by a Party other than the Registrant [ ] Check the appropriate box: [ ]Preliminary Proxy Statement [ ]Confidential, for U |
|
| April 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant [X] Filed by a Party other than the Registrant [ ] Check the appropriate box: [ ]Preliminary Proxy Statement [ ]Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) [ |
|
| April 25, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): April 19, 2023 Bellerophon Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-36845 47-3116175 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| March 31, 2023 |
Bellerophon Provides Clinical Program Update and Reports Full-Year 2022 Financial Results Exhibit 99.1 Bellerophon Provides Clinical Program Update and Reports Full-Year 2022 Financial Results - Completed Enrollment in INOpulse® REBUILD Phase 3 trial; Pivotal Top-line Data Expected in Mid-2023 - Signed License Agreement with Baylor BioSciences to Commercialize INOpulse® in Greater China - Strengthened Balance Sheet Through $5 Million Registered Direct Offering with Life Sciences-focuse |
|
| March 31, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 31, 2023 Bellerophon Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-36845 47-3116175 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| March 31, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-368 |
|
| March 17, 2023 |
BLPH / Bellerophon Therapeutics Inc / TANG CAPITAL PARTNERS LP Passive Investment Securities and Exchange Commission Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| March 17, 2023 |
EX-99.1 2 ex991.htm EXHIBIT 99.1 Exhibit 99.1 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k)(1) promulgated under the Securities Exchange Act of 1934, the undersigned agree to the joint filing of a Statement on Schedule 13G (including any and all amendments thereto) with respect to the Common Stock, $0.01 par value per share, of Bellerophon Therapeutics, Inc. and further agree to the fili |
|
| March 14, 2023 |
BLPH / Bellerophon Therapeutics Inc / PERCEPTIVE ADVISORS LLC - SC 13G Passive Investment SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Bellerophon Therapeutics, Inc. (Name of Issuer) Common Stock, $0.01 par value per share (Title of Class of Securities) 078771300 (CUSIP Number) March 6, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to desig |
|
| March 14, 2023 |
EX-99.1 EXHIBIT 1 AGREEMENT The persons below hereby agree that the Schedule 13G to which this agreement is attached as an exhibit, as well as all future amendments to such Schedule 13G, shall be filed on behalf of each of them. This agreement is intended to satisfy the requirements of Rule 13d-1(k)(1)(iii) under the Securities Exchange Act of 1934. Date: March 14, 2023 PERCEPTIVE ADVISORS LLC By: |
|
| March 6, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 3, 2023 Bellerophon Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-36845 47-3116175 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| March 6, 2023 |
Filed Pursuant to Rule 424(b)(5) Registration No. 333-239473 PROSPECTUS SUPPLEMENT (To the Prospectus dated July 2, 2020) 718,474 Shares of Common Stock Pre-Funded Warrants to Purchase up to 1,781,526 Shares of Common Stock Pursuant to this prospectus supplement and the accompanying prospectus, we are offering directly 718,474 shares of our common stock and pre-funded warrants to purchase 1,781,52 |
|
| March 6, 2023 |
Exhibit 4.1 Form of Pre-Funded Warrant Bellerophon Therapeutics, Inc. FORM OF WARRANT TO PURCHASE COMMON STOCK Number of Shares: 1,781,526 Warrant No. [ ] Original Issue Date: March [ ], 2023 Bellerophon Therapeutics, Inc., a Delaware corporation (the “Company”), hereby certifies that, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, [ ] or its reg |
|
| March 6, 2023 |
Exhibit 10.1 Subscription Agreement This Subscription Agreement (this “Agreement”) is entered into as of March 3, 2023 by and between Bellerophon Therapeutics, Inc., a Delaware corporation (the “Company”), and the investor set forth on the signature page hereto (the “Investor”). Recitals A.The Company has authorized the sale and issuance hereunder of 718,474 shares (the “Shares”) of Common Stock, |
|
| March 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 3, 2023 Bellerophon Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-36845 47-3116175 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| February 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 9, 2023 Bellerophon Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-36845 47-3116175 (State or Other Jurisdiction of Incorporation) (Commis |
|
| February 9, 2023 |
Exhibit 99.1 Bellerophon Therapeutics Receives IND Clearance from China NMPA to Conduct Phase 3 Clinical Trial in China for INOpulse® in Fibrotic Interstitial Lung Disease China NPMA accepts the use of Moderate to Vigorous Physical Activity (MVPA) as the primary endpoint WARREN, N.J., February 9, 2023 – Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stag |
|
| January 19, 2023 |
Filed Pursuant to Rule 424(b)(5) Registration No. 333-239473 PROSPECTUS SUPPLEMENT (To Prospectus Supplement dated July 17, 2020 To Prospectus dated July 2, 2020) Up to $6,000,000 Common Stock This prospectus supplement amends and supplements the information in the prospectus, dated July 2, 2020, filed with the Securities and Exchange Commission as a part of our registration statement on Form S-3 |
|
| January 18, 2023 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 18, 2023 Bellerophon Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-36845 47-3116175 (State or Other Jurisdiction of Incorporation) (Commis |
|
| January 18, 2023 |
Exhibit 99.1 Bellerophon Therapeutics Announces Completion of Enrollment in Phase 3 REBUILD Study for INOpulse® in Fibrotic Interstitial Lung Disease Enrollment concludes earlier than anticipated; pivotal top-line data now expected mid-2023 WARREN, N.J., January 18, 2023 – Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company focus |
|
| January 5, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 4, 2023 Bellerophon Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-36845 47-3116175 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| November 14, 2022 |
Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| November 14, 2022 |
Bellerophon Provides Clinical Program Update and Reports Third Quarter 2022 Financial Results Exhibit 99.1 ? ? Bellerophon Provides Clinical Program Update and Reports Third Quarter 2022 Financial Results ? - Ongoing INOpulse? REBUILD Phase 3 trial enrollment completion expected in the first quarter of 2023, with pivotal top-line data readout anticipated in the third quarter of 2023 ? WARREN, N.J., November 14, 2022 ? Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (?Bellerophon? or the ?Com |
|
| November 14, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 14, 2022 ? Bellerophon Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) ? ? ? ? ? ? Delaware 001-36845 47-3116175 (State or Other Jurisdiction of Incor |
|
| September 27, 2022 |
Exhibit 99.1 ? ? Bellerophon Announces FDA Acceptance of Change to Ongoing Phase 3 REBUILD Study of INOpulse? for Treatment of Fibrotic Interstitial Lung Disease ? - New study size of 140 patients for the REBUILD Study, without modifying trial objective or endpoints and maintaining power of >90% for the primary endpoint - Independent Data Monitoring Committee agreed that the new targeted study siz |
|
| September 27, 2022 |
Financial Statements and Exhibits, Other Events ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K ? CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): September 27, 2022 ? Bellerophon Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) ? ? ? ? ? ? Delaware 001-36845 47-3116175 (State or Other Jurisdiction of In |
|
| August 15, 2022 |
Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| August 15, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 15, 2022 ? Bellerophon Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) ? ? ? ? ? ? Delaware 001-36845 47-3116175 (State or Other Jurisdiction of Incorpo |
|
| August 15, 2022 |
Bellerophon Provides Clinical Program Update and Reports Second Quarter 2022 Financial Results Exhibit 99.1 ? ? Bellerophon Provides Clinical Program Update and Reports Second Quarter 2022 Financial Results ? WARREN, N.J., August 15, 2022 ? Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (?Bellerophon? or the ?Company?), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary diseases, today provided a clinical program update and reported financial result |
|
| June 7, 2022 |
Submission of Matters to a Vote of Security Holders ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K ? CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 1, 2022 ? Bellerophon Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) ? ? ? ? ? ? Delaware 001-36845 47-3116175 (State or Other Jurisdiction of Incorpor |
|
| May 11, 2022 |
Bellerophon Provides Clinical Program Update and Reports First Quarter 2022 Financial Results Exhibit 99.1 ? ? Bellerophon Provides Clinical Program Update and Reports First Quarter 2022 Financial Results ? WARREN, N.J., May 11, 2022 ? Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (?Bellerophon? or the ?Company?), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary diseases, today provided a clinical program update and reported financial results fo |
|
| May 11, 2022 |
Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| May 11, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 11, 2022 ? Bellerophon Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) ? ? ? ? ? ? Delaware 001-36845 47-3116175 (State or Other Jurisdiction of Incorporat |
|
| April 25, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant [X] Filed by a Party other than the Registrant [ ] Check the appropriate box: [ ]Preliminary Proxy Statement [ ]Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) [ |
|
| April 25, 2022 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant [X] Filed by a Party other than the Registrant [ ] Check the appropriate box: [ ]Preliminary Proxy Statement [ ]Confidential, for Use of the Commission Only (as permitted by R |
|
| March 31, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K Table of Contents ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. |
|
| March 31, 2022 |
Bellerophon Provides Clinical Program Update and Reports Full-Year 2021 Financial Results Exhibit 99.1 ? ? Bellerophon Provides Clinical Program Update and Reports Full-Year 2021 Financial Results ? WARREN, N.J., March 31, 2022 ? Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (?Bellerophon? or the ?Company?), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary diseases, today provided a clinical program update and reported financial results for |
|
| March 31, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 31, 2022 ? Bellerophon Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) ? ? ? ? ? ? Delaware 001-36845 47-3116175 (State or Other Jurisdiction of Incorpor |
|
| February 14, 2022 |
BLPH / Bellerophon Therapeutics Inc / New Mountain Investments II, LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 6)* Bellerophon Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) 078771300 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designa |
|
| January 28, 2022 |
Form of Restricted Sock Unit Agreement under 2015 Equity Incentive Plan Exhibit 10.1 ? BELLEROPHON THERAPEUTICS, INC. Restricted Stock Unit Grant Notice Restricted Stock Unit Award Grant under the Company?s 2015 Equity Incentive Plan Name of recipient (the ?Participant?): ? Grant Date of this restricted stock unit award (the ?Grant Date?): ? Number of shares of the Company?s Common Stock subject to this restricted stock unit award (the ?Restricted Shares?): ? Number, |
|
| January 28, 2022 |
? UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K ? CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 26, 2022 ? Bellerophon Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) ? ? ? ? ? ? Delaware 001-36845 47-3116175 (State or Other Jurisdiction of Inco |
|
| January 5, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K ? CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 5, 2022 ? Bellerophon Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) ? ? ? ? ? ? Delaware 001-36845 47-3116175 (State or Other Jurisdiction of Incor |
|
| January 5, 2022 |
Exhibit 99.1 Company Presentation I January 2022Bellerophon Therapeutics Bellerophon Therapeutics Overview | January 20222 Forward Looking StatementsThispresentationcontainsforward-lookingstatementsthatinvolvesubstantialrisksanduncertainties.Allstatements,otherthanstatementsofhistoricalfacts,containedinthispresentation,includingstatementsregardingourstrategy,futureoperations,futurefinancialpositio |
|
| January 4, 2022 |
? UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K/A (Amendment No. 1) ? CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): September 30, 2021 ? Bellerophon Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) ? ? ? ? ? ? Delaware 001-36845 47-3116175 (State or Othe |
|
| December 17, 2021 |
Exhibit 99.1 ? ? Bellerophon Reports Positive Top-Line Data from Phase 2 Acute Dose Escalation Study of INOpulse? for Treatment of Pulmonary Hypertension Associated with Sarcoidosis ? Phase 2 results provide clinically meaningful reduction in pulmonary vascular resistance; Company intends to design multi-dose Phase 2b trial ? Treatment was safe and well-tolerated, with no treatment-emergent advers |
|
| December 17, 2021 |
Financial Statements and Exhibits, Other Events ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K ? CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): December 17, 2021 ? Bellerophon Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) ? ? ? ? ? ? Delaware 001-36845 47-3116175 (State or Other Jurisdiction of Inc |
|
| November 15, 2021 |
Bellerophon Provides Clinical Program Update and Reports Third Quarter 2021 Financial Results Exhibit 99.1 ? ? Bellerophon Provides Clinical Program Update and Reports Third Quarter 2021 Financial Results ? WARREN, N.J., November 15, 2021 ? Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (?Bellerophon? or the ?Company?), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary diseases, today provided a clinical program update and reported financial resul |
|
| November 15, 2021 |
Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| November 15, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 15, 2021 Bellerophon Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-36845 47-3116175 (State or Other Jurisdiction of Incorporation) (Commi |
|
| November 12, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 11, 2021 Bellerophon Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-36845 47-3116175 (State or Other Jurisdiction of Incorporation) (Commi |
|
| October 12, 2021 |
? UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K ? CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): October 7, 2021 ? Bellerophon Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) ? ? ? ? ? ? Delaware 001-36845 47-3116175 (State or Other Jurisdiction of Incor |
|
| October 6, 2021 |
? UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K ? (Amendment No. 1) ? CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): September 30, 2021 ? Bellerophon Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) ? ? ? ? ? ? Delaware 001-36845 47-3116175 (State or Othe |
|
| August 31, 2021 |
? UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K ? (Amendment No. 1) ? CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 25, 2021 ? Bellerophon Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) ? ? ? ? ? ? Delaware 001-36845 47-3116175 (State or Other J |
|
| August 5, 2021 |
Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| August 5, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 5, 2021 ? Bellerophon Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) ? ? ? ? ? ? Delaware 001-36845 47-3116175 (State or Other Jurisdiction of Incorpor |
|
| August 5, 2021 |
Bellerophon Provides Clinical Program Update and Reports Second Quarter 2021 Financial Results Exhibit 99.1 ? ? Bellerophon Provides Clinical Program Update and Reports Second Quarter 2021 Financial Results ? WARREN, N.J., August 5, 2021 ? Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (?Bellerophon? or the ?Company?), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary diseases, today provided a clinical program update and reported financial results |
|
| June 11, 2021 |
Submission of Matters to a Vote of Security Holders ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K/A ? (Amendment No. 1) ? CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 26, 2021 ? Bellerophon Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) ? ? ? ? ? ? Delaware 001-36845 47-3116175 (State or Other Ju |
|
| June 11, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 ? FORM S-8 ? REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 ? Bellerophon Therapeutics, Inc. (Exact name of registrant as specified in its charter) ? or Delaware 47-3116175 (State or other jurisdiction of incorporation or organization) (IRS Employer Identification No.) ? ? 184 Liberty Corner Road, Suite 302 Warren, Ne |
|
| May 26, 2021 |
Exhibit 99.1 ? ? ? Bellerophon Appoints Naseem Amin, M.D. as Chairman of its Board of Directors ? ? Dr. Amin Has Served as an Independent Director Since 2015 and Succeeds Jonathan Peacock Following Mr. Peacock?s Retirement from the Company?s Board ? ? WARREN, N.J., May 26, 2021 ? Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (?Bellerophon? or the ?Company?), a clinical-stage biotherapeutics compan |
|
| May 26, 2021 |
Financial Statements and Exhibits, Other Events, Submission of Matters to a Vote of Security Holders ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 26, 2021 ? Bellerophon Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) ? ? ? ? ? ? Delaware 001-36845 47-3116175 (State or Other Jurisdiction of Incorporat |
|
| May 11, 2021 |
Bellerophon Provides Clinical Program Update and Reports First Quarter 2021 Financial Results Exhibit 99.1 ? ? Bellerophon Provides Clinical Program Update and Reports First Quarter 2021 Financial Results ? WARREN, N.J., May 11, 2021 ? Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (?Bellerophon? or the ?Company?), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary diseases, today provided a clinical program update and reported financial results fo |
|
| May 11, 2021 |
Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| May 11, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 11, 2021 ? Bellerophon Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) ? ? ? ? ? ? Delaware 001-36845 47-3116175 (State or Other Jurisdiction of Incorporat |
|
| April 28, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No.1)* Bellerophon Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) 078771300 (CUSIP Number) Name: Theodore Wang c/o Puissance Capital Management LP 950 Third Avenue, 25th Floor New York, New York 10022 T |
|
| April 13, 2021 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant [X] Filed by a Party other than the Registrant [ ] Check the appropriate box: [ ]Preliminary Proxy Statement [ ]Confidential, for Use of the Commission Only (as permitted by R |
|
| April 13, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant [X] Filed by a Party other than the Registrant [ ] Check the appropriate box: [ ]Preliminary Proxy Statement [ ]Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) [ |
|
| March 31, 2021 |
? UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 25, 2021 ? Bellerophon Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) ? ? ? ? ? ? Delaware 001-36845 47-3116175 (State or Other Jurisdiction of Incorpor |
|
| March 11, 2021 |
Exhibit 4.5 ? DESCRIPTION OF THE REGISTRANT?S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 ? As of March 8, 2021, Bellerophon Therapeutics, Inc. (?Bellerophon,? ?we,? ?us? or the ?Company?) had one class of securities registered under Section 12(b) of the Securities Exchange Act of 1934, as amended (the ?Exchange Act?): Common Stock, $0.01 par value per share |
|
| March 11, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 11, 2021 ? Bellerophon Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) ? ? ? ? ? ? Delaware 001-36845 47-3116175 (State or Other Jurisdiction of Incorpor |
|
| March 11, 2021 |
Exhibit 99.1 ? Bellerophon Provides Clinical Program Update and Reports Fourth Quarter and Full-Year 2020 Financial Results ? WARREN, N.J., March 11, 2021 ? Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (?Bellerophon? or the ?Company?), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary diseases, today provided a clinical program update and reported finan |
|
| March 11, 2021 |
Table of Contents ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. |
|
| February 12, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 5)* Bellerophon Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) 078771300 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designa |
|
| January 11, 2021 |
Regulation FD Disclosure, Financial Statements and Exhibits - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 11, 2021 Bellerophon Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-36845 47-3116175 (State or Other Jurisdiction of Incorporation) (Commis |
|
| January 11, 2021 |
bellerophoncorporatedeck 2021 Company Presentation I Company Presentation I January 2021 Bellerophon Therapeutics 2021 Company Presentation I 2 This presentation contains forward-looking statements that involve substantial risks and uncertainties. |
|
| December 1, 2020 |
Financial Statements and Exhibits, Other Events - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): December 1, 2020 Bellerophon Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-36845 47-3116175 (State or Other Jurisdiction of Incorporation) (Commis |
|
| December 1, 2020 |
Exhibit 99.1 Bellerophon Therapeutics Announces First Patient Enrolled in Phase 3 REBUILD Study Evaluating INOpulse® for the Treatment of Fibrotic Interstitial Lung Disease WARREN, N.J., Dec. 1, 2020 – Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary and infectious diseases, |
|
| November 23, 2020 |
Financial Statements and Exhibits, Other Events - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 23, 2020 Bellerophon Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-36845 47-3116175 (State or Other Jurisdiction of Incorporation) (Commi |
|
| November 23, 2020 |
Exhibit 99.1 Bellerophon Therapeutics Announces Results of Interim Analysis of Phase 3 COViNOX Study of INOpulse® for the Treatment of COVID-19 WARREN, N.J., Nov. 23, 2020 – Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary and infectious diseases, today announced that the in |
|
| November 5, 2020 |
Bellerophon Provides Clinical Program Update and Reports Third Quarter 2020 Financial Results Exhibit 99.1 Bellerophon Provides Clinical Program Update and Reports Third Quarter 2020 Financial Results WARREN, N.J., Nov. 5, 2020 – Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary and infectious diseases, today provided a clinical program update and reported financial r |
|
| November 5, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 5, 2020 Bellerophon Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-36845 47-3116175 (State or Other Jurisdiction of Incorporation) (Commis |
|
| November 5, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-36845 Beller |
|
| August 5, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ý QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-36845 Bellerophon |
|
| August 5, 2020 |
Bellerophon Provides Clinical Program Update and Reports Second Quarter 2020 Financial Results Exhibit 99.1 Bellerophon Provides Clinical Program Update and Reports Second Quarter 2020 Financial Results WARREN, N.J., August 5, 2020 - Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary and infectious diseases, today provided a clinical program update and reported financia |
|
| August 5, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 5, 2020 Bellerophon Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-36845 47-3116175 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| July 17, 2020 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July 17, 2020 Bellerophon Therapeutics, Inc. (Exact name of registrant as specified in charter) Delaware 001-36845 47-3116175 (State or other jurisdiction of incorporation) (Commissio |
|
| July 17, 2020 |
Exhibit 10.1 Execution Version OPEN MARKET SALE AGREEMENTSM July 17, 2020 JEFFERIES LLC 520 Madison Avenue New York, New York 10022 Ladies and Gentlemen: Bellerophon Therapeutics, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell from time to time through Jefferies LLC, as sales agent and/or principal (the “Agent”), shares |
|
| July 17, 2020 |
Up to $40,000,000 Common Stock Filed Pursuant to Rule 424(b)(5) Registration No. 333-239473 Prospectus Supplement (To Prospectus dated July 2, 2020) Up to $40,000,000 Common Stock We have entered into an Open Market Sale AgreementSM, or the sales agreement, with Jefferies LLC, or Jefferies, relating to the sale of shares of our common stock offered by this prospectus supplement. In accordance with the terms of the sales agreeme |
|
| July 13, 2020 |
Exhibit 99.1 Bellerophon Therapeutics Announces First Patient Treated in Phase 3 Clinical Study of INOpulse® Inhaled Nitric Oxide Therapy for COVID-19 Initiation of the COViNOX Study Follows the Conclusion of the FDA Emergency Access Program Through Which 180 Patients with COVID-19 Were Treated in the United States WARREN, N.J., July 13, 2020 - Bellerophon Therapeutics, Inc. (Nasdaq: BLPH), a clin |
|
| July 13, 2020 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July 13, 2020 Bellerophon Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-36845 47-3116175 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| July 1, 2020 |
Bellerophon Therapeutics, Inc. 184 Liberty Corner Road, Suite 302 Warren, New Jersey 07059 July 1, 2020 Via EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Mail Stop 3561 Washington, D.C. 20549 Re: Bellerophon Therapeutics, Inc. Registration Statement on Form S-3 Filed on June 26, 2020 File No. 333-239473 Acceleration Request Ladies and Gentlemen: Pursua |
|
| July 1, 2020 |
Bellerophon Therapeutics, Inc. 184 Liberty Corner Road, Suite 302 Warren, New Jersey 07059 July 1, 2020 Via EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Mail Stop 3561 Washington, D.C. 20549 Re: Bellerophon Therapeutics, Inc. Registration Statement on Form S-3 Filed on June 26, 2020 File No. 333-239473 Acceleration Request Ladies and Gentlemen: Pursua |
|
| June 26, 2020 |
Exhibit 4.6 BELLEROPHON THERAPEUTICS, INC. Issuer AND [ ] Trustee INDENTURE Dated as of [ ] Senior Debt Securities 1 CROSS-REFERENCE TABLE (1) Section of Trust Indenture Act of 1939, as Amended Section of Indenture 310(a). 7.09 310(b). 7.08 7.10 310(c). Inapplicable 311(a). 7.13(a) 311(b). 7.13(b) 311(c). Inapplicable 312(a) 5.02(a) 312(b). 5.02(b) 312(c). 5.02(c) 313(a). 5.04(a) 313(b). 5.04(a) 3 |
|
| June 26, 2020 |
As filed with the Securities and Exchange Commission on June 26, 2020 Registration No. |
|
| June 26, 2020 |
Exhibit 4.7 BELLEROPHON THERAPEUTICS, INC. Issuer AND [ ] Trustee INDENTURE Dated as of [ ] Subordinated Debt Securities CROSS-REFERENCE TABLE (1) Section of Trust Indenture Act of 1939, as Amended Section of Indenture 310(a). 7.09 310(b). 7.08 7.10 310(c). Inapplicable 311(a). 7.13(a) 311(b). 7.13(b) 311(c). Inapplicable 312(a). 5.02(a) 312(b). 5.02(b) 312(c). 5.02(c) 313(a). 5.04(a) 313(b). 5.04 |
|
| June 12, 2020 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 11, 2020 Bellerophon Therapeutics, Inc. (Exact name of registrant as specified in charter) Delaware 001-36845 47-3116175 (State or other jurisdiction of incorporation) (Commissio |
|
| May 22, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 3)* Bellerophon Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) 078771300 (CUSIP Number) Name: Theodore Wang c/o Puissance Capital Management LP 950 Third Avenue, 25th Floor New York, New York 10022 |
|
| May 22, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. )* Bellerophon Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) 078771300 (CUSIP Number) Name: Theodore Wang c/o Puissance Capital Management LP 950 Third Avenue, 25th Floor New York, New York 10022 T |
|
| May 22, 2020 |
FORM OF SUBSCRIPTION AGREEMENT FORM OF SUBSCRIPTION AGREEMENT Bellerophon Therapeutics, Inc. 184 Liberty Corner Road, Suite 302 Warren, New Jersey 07059 Ladies and Gentlemen: The undersigned (the "Investor") hereby confirms its agreement with you as follows: 1. This Subscription Agreement (this "Agreement") is made as of the date set forth below between Bellerophon Therapeutics, Inc., a Delaware corporation (the "Company"), and |
|
| May 20, 2020 |
Exhibit 10.1 May 18, 2020 Personal and Confidential Angel Pond Capital LLC 950 Third Avenue, 25th Floor New York, NY 10022 THIS AGREEMENT (the “Agreement”) is entered into as of May 18, 2020 between Bellerophon Therapeutics, Inc. (the “Company”) and Angel Pond Capital LLC (“Advisor”). The Company and Advisor shall collectively be referred to as the “Parties” and each a “Party.” RECITALS A. The Com |
|
| May 20, 2020 |
Filed Pursuant to Rule 424(b)(5) Registration No. 333-225878 PROSPECTUS SUPPLEMENT (To Prospectus dated July 6, 2018) 1,153,846 Shares Common Stock We are offering 1,153,846 shares of common stock, par value $0.01 per share, in this offering. The purchase price for each share of common stock is $13.00. Our common stock is listed on The Nasdaq Capital Market under the symbol “BLPH”. On May 18, 2020 |
|
| May 20, 2020 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 18, 2020 Bellerophon Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-36845 47-3116175 (State or Other Jurisdiction of Incorporation) (Commission |
|
| May 20, 2020 |
Exhibit 99.2 Bellerophon Therapeutics Announces Pricing of Public Offering of Common Stock and Concurrent Registered Direct Offering WARREN, N.J., May 19, 2020 (GLOBE NEWSWIRE) — Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”) today announced the pricing of offerings for an aggregate of 3,076,923 shares of its common stock at a public offering price of $13.00 per sha |
|
| May 20, 2020 |
Filed Pursuant to Rule 424(b)(5) Registration No. 333-225878 PROSPECTUS SUPPLEMENT (To Prospectus dated July 6, 2018) 1,923,077 Shares Common Stock We are offering 1,923,077 shares of our common stock. Our common stock is listed on The Nasdaq Capital Market under the symbol “BLPH.” On May 18, 2020, the last reported sale price of our common stock on The Nasdaq Capital Market was $16.16 per share. |
|
| May 20, 2020 |
Bellerophon Therapeutics Announces Proposed Public Offering of Common Stock Exhibit 99.1 Bellerophon Therapeutics Announces Proposed Public Offering of Common Stock WARREN, N.J., May 18, 2020 – Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”) today announced that it intends to offer and sell shares of its common stock in an underwritten registered public offering. All of the shares in the offering are to be sold by Bellerophon. Bellerophon al |
|
| May 20, 2020 |
Exhibit 1.1 Execution Version 1,923,077 Shares of Common Stock Bellerophon Therapeutics, Inc. UNDERWRITING AGREEMENT May 18, 2020 JEFFERIES LLC As Representative of the several Underwriters c/o JEFFERIES LLC 520 Madison Avenue New York, New York 10022 Ladies and Gentlemen: Introductory. Bellerophon Therapeutics, Inc., a Delaware corporation (the “Company”), proposes to issue and sell to the severa |
|
| May 20, 2020 |
Exhibit 4.1 FORM OF SUBSCRIPTION AGREEMENT Bellerophon Therapeutics, Inc. 184 Liberty Corner Road, Suite 302 Warren, New Jersey 07059 Ladies and Gentlemen: The undersigned (the “Investor”) hereby confirms its agreement with you as follows: 1. This Subscription Agreement (this “Agreement”) is made as of the date set forth below between Bellerophon Therapeutics, Inc., a Delaware corporation (the “Co |
|
| May 18, 2020 |
Filed Pursuant to Rule 424(b)(5) Registration No. 333-225878 The information in this preliminary prospectus supplement and the accompanying prospectus is not complete and may be changed. A registration statement relating to the securities has been declared effective by the Securities and Exchange Commission. This preliminary prospectus supplement and the accompanying prospectus are not an offer to |
|
| May 11, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ý QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2020 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-36845 Belleropho |
|
| May 11, 2020 |
Bellerophon Provides Clinical Program Update and Reports First Quarter 2020 Financial Results Exhibit 99.1 Bellerophon Provides Clinical Program Update and Reports First Quarter 2020 Financial Results WARREN, N.J., May 11, 2020 - Bellerophon Therapeutics, Inc. (Nasdaq: BLPH), (“Bellerophon” or the “Company”) a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary and infectious lung diseases, today provided a clinical program update and reported financ |
|
| May 11, 2020 |
Exhibit 99.1 Bellerophon Therapeutics Announces FDA Clears Initiation of Phase 3 Study for INOpulse® Inhaled Nitric Oxide Therapy to Treat COVID-19 WARREN, N.J., May 11, 2020 - Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary and infectious lung diseases, today announced tha |
|
| May 11, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 11, 2020 Bellerophon Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-36845 47-3116175 (State or Other Jurisdiction of Incorporation) (Commission |
|
| May 11, 2020 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 11, 2020 Bellerophon Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-36845 47-3116175 (State or Other Jurisdiction of Incorporation) (Commission |
|
| April 27, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant [X] Filed by a Party other than the Registrant [ ] Check the appropriate box: [ ] Preliminary Proxy Statement [ ] Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) |
|
| April 23, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant [X] Filed by a Party other than the Registrant [ ] Check the appropriate box: [ ] Preliminary Proxy Statement [ ] Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) |
|
| April 8, 2020 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): April 8, 2020 Bellerophon Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-36845 47-3116175 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| April 8, 2020 |
Exhibit 99.1 Bellerophon Therapeutics Submits Investigational New Drug Application to Study INOpulse® Inhaled Nitric Oxide Therapy for the Treatment of COVID-19 IND Submission Follows Completed Treatment of Several COVID-19 Patients with INOpulse Under FDA Authorized Emergency Expanded Access Program WARREN, N.J., April 8, 2020 - Bellerophon Therapeutics, Inc. (Nasdaq: BLPH), a clinical-stage biot |
|
| April 6, 2020 |
the description of our common stock contained in Exhibit 4.5 in our Form 10-K filed on April 6, 2020 Exhibit 4.5 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 As of April 3, 2020, Bellerophon Therapeutics, Inc. (“Bellerophon,” “we,” “us” or the “Company”) had one class of securities registered under Section 12(b) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”): Common Stock, $0.01 par value per share (“C |
|
| April 6, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): April 6, 2020 Bellerophon Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-36845 47-3116175 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| April 6, 2020 |
Exhibit 99.1 Bellerophon Provides Clinical Program Update and Reports Fourth Quarter and Full-Year 2019 Financial Results WARREN, N.J., April 6, 2020 - Bellerophon Therapeutics, Inc. (Nasdaq: BLPH), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary diseases, today provided a clinical program update and reported financial results for the fourth quarter an |
|
| April 6, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019 or ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-36845 Bellerophon The |
|
| March 31, 2020 |
1,275,000 SHARES OF COMMON STOCK Filed Pursuant to Rule 424(b)(5) Registration File No. 333-225878 PROSPECTUS SUPPLEMENT (To Prospectus dated July 6, 2018) 1,275,000 SHARES OF COMMON STOCK We are offering an aggregate of 1,275,000 shares of our common stock, par value $0.01 per share (the “Common Stock”), to certain institutional and accredited investors at a purchase price equal to $12.00 per share. Our Common Stock is listed on |
|
| March 31, 2020 |
bellerophoncovid19deckma Bellerophon Therapeutics COVID-19 Overview I March 2020 Forward Looking Statements This presentation contains forward-looking statements that involve substantial risks and uncertainties. |
|
| March 31, 2020 |
BLPH / Bellerophon Therapeutics, Inc. NT 10-K - - NT 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check One): x Form 10-K ¨ Form 20-F ¨ Form 11-K ¨ Form 10-Q ¨ Form 10-D ¨ Form N-SAR ¨ Form N-CSR For Period Ended: December 31, 2019 ¨ Transition Report on Form 10-K ¨ Transition Report on Form 20-F ¨ Transition Report on Form 11-K ¨ Transition Report on Form 10-Q ¨ Transition Report o |
|
| March 31, 2020 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 31, 2020 Bellerophon Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-36845 47-3116175 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| March 30, 2020 |
Exhibit 99.1 Bellerophon Therapeutics Announces First Patient Treated with INOpulse® Inhaled Nitric Oxide Therapy for COVID-19 WARREN, N.J., Mar. 30, 2020 - Bellerophon Therapeutics, Inc. (Nasdaq: BLPH), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary diseases, today announced that expanded access treatment with the INOpulse® inhaled nitric oxide syste |
|
| March 30, 2020 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 30, 2020 Bellerophon Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-36845 47-3116175 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| March 30, 2020 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 30, 2020 BELLEROPHON THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36845 47-3116175 (state or other jurisdiction of incorporation) (Comm |
|
| March 30, 2020 |
Exhibit 1.1 March 20, 2020 STRICTLY CONFIDENTIAL Bellerophon Therapeutics, Inc. 184 Liberty Corner Road, Suite 302 Warren, New Jersey 07059 Attn: Fabian Tenenbaum, Chief Executive Officer Dear Mr. Tenenbaum: This letter agreement (this “Agreement”) constitutes the agreement between Bellerophon Therapeutics, Inc. (the “Company”) and H.C. Wainwright & Co., LLC (“Wainwright”), that Wainwright shall s |
|
| March 30, 2020 |
Bellerophon Announces $15.3 Million Registered Direct Offering Priced At-the-Market Exhibit 99.1 Bellerophon Announces $15.3 Million Registered Direct Offering Priced At-the-Market WARREN, N.J., Mar. 30, 2020 - Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company, today announced that it has entered into definitive agreements with several healthcare-focused institutional investors for the purchase and sale of 1,2 |
|
| March 30, 2020 |
Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of March 30, 2020, between Bellerophon Therapeutics, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the terms and con |
|
| March 20, 2020 |
FDA Grants Bellerophon Emergency Expanded Access for INOpulse® for the Treatment of COVID-19 Virus Exhibit 99.1 FDA Grants Bellerophon Emergency Expanded Access for INOpulse® for the Treatment of COVID-19 Virus WARREN, N.J., Mar. 20, 2020 - Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company, today announced that the U.S. Food and Drug Administration (FDA) has granted emergency expanded access allowing its proprietary inhaled |
|
| March 20, 2020 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 20, 2020 Bellerophon Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-36845 47-3116175 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| March 10, 2020 |
Exhibit 99.1 Bellerophon Announces Agreement with the FDA on its Planned Pivotal Phase 3 Study for the Treatment of Pulmonary Hypertension Associated with Pulmonary Fibrosis WARREN, N.J., Mar. 10, 2020 - Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company, today announced the successful completion of its End-of-Phase 2 Meetings w |
|
| March 10, 2020 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 10, 2020 Bellerophon Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-36845 47-3116175 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| February 18, 2020 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 18, 2020 Bellerophon Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-36845 47-3116175 (State or Other Jurisdiction of Incorporation) (Commi |
|
| February 18, 2020 |
Exhibit 99.1 Bellerophon Reports Positive Top-Line Data from an Ancillary Acute Hemodynamic Study of INOpulse® for Treatment of Pulmonary Hypertension Associated with Pulmonary Fibrosis WARREN, N.J., February 18, 2020 - Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company, today announced positive top-line data from a recently com |
|
| February 14, 2020 |
BLPH / Bellerophon Therapeutics, Inc. / VENROCK ASSOCIATES IV L P - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 3)* Bellerophon Therapeutics, Inc. (Name of Issuer) Common Stock, $0.01 par value (Title of Class of Securities) 078771102 (CUSIP Number) December 31, 2019 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the r |
|
| February 10, 2020 |
BLPH / Bellerophon Therapeutics, Inc. / New Mountain Investments II, LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 4)* Bellerophon Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) 078771102 (CUSIP Number) December 31, 2019 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designa |
|
| February 7, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 5, 2020 Bellerophon Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-36845 47-3116175 (State or Other Jurisdiction of Incorporation) (Commis |
|
| February 7, 2020 |
CERTIFICATE OF AMENDMENT OF THE RESTATED CERTIFICATE OF INCORPORATION OF BELLEROPHON THERAPEUTICS, INC. |
|
| February 7, 2020 |
Bellerophon Announces 1-for-15 Reverse Stock Split Exhibit 99.1 Bellerophon Announces 1-for-15 Reverse Stock Split WARREN, N.J., Feb. 7, 2020 (GLOBE NEWSWIRE) - Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company, today announced the filing of a certificate of amendment to its amended and restated certificate of incorporation with the Secretary of the State of Delaware to effect |
|
| January 29, 2020 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 29,2020 Bellerophon Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-36845 47-3116175 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| January 7, 2020 |
BLPH / Bellerophon Therapeutics, Inc. DEF 14A - - DEF 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant [X] Filed by a Party other than the Registrant [ ] Check the appropriate box: [ ] Preliminary Proxy Statement [ ] Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) |
|
| December 27, 2019 |
BLPH / Bellerophon Therapeutics, Inc. PRE 14A - - PRE 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant [X] Filed by a Party other than the Registrant [ ] Check the appropriate box: [X] Preliminary Proxy Statement [ ] Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) |
|
| December 17, 2019 |
bellerophoncreditfacilit Exhibit 10.1 Bellerophon Therapeutics, Inc. Binding Term Sheet and Agreement for Line of Credit Facility This Binding Term Sheet and Agreement for Line of Credit Facility (the “Agreement”) is entered into as of December 16, 2019, by and among the signatories hereto. NOW, THEREFORE, in consideration of the mutual agreements and covenants contained herein and for other good |
|
| December 17, 2019 |
bellerophoncohort2callde Bellerophon Therapeutics iNO-PF Cohort 2 Top-Line Data Call December 17, 2019 Nasdaq: BLPH Forward Looking Statements This presentation contains forward-looking statements that involve substantial risks and uncertainties. |
|
| December 17, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): December 17, 2019 Bellerophon Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-36845 47-3116175 (State or Other Jurisdiction of Incorporation) (Commi |
|
| December 17, 2019 |
Exhibit 99.1 Bellerophon Announces Positive Top-line Results from Cohort 2 of Phase 2/3 Study of INOpulse® for Treatment of Pulmonary Hypertension Associated with Interstitial Lung Disease Statistically Significant Improvement Demonstrated in Moderate to Vigorous Physical Activity Bellerophon Intends to Initiate Pivotal Phase 3 in First Quarter of 2020 Company Enters Into $10M Convertible Financin |
|
| November 12, 2019 |
Exhibit 99.1 Bellerophon Announces Positive Initial Data from Acute Hemodynamic Dose Escalation Study of INOpulse® for Treatment of Pulmonary Hypertension Associated with Interstitial Lung Disease WARREN, N.J., November 12, 2019 - Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company, today announced positive initial data from an a |
|
| November 12, 2019 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 12, 2019 Bellerophon Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-36845 47-3116175 (State or Other Jurisdiction of Incorporation) (Commi |
|
| November 7, 2019 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 7, 2019 Bellerophon Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-36845 47-3116175 (State or Other Jurisdiction of Incorporation) (Commis |
|
| November 7, 2019 |
Exhibit 99.1 Bellerophon Presents New Data from Cohort 1 of Ongoing Phase 2/3 Study of INOpulse® for Treatment of Pulmonary Hypertension Associated with Interstitial Lung Disease at Pulmonary Fibrosis Foundation Summit 2019 Data Include New Results from Subgroup Analysis of Cohort 1 Further Demonstrating Benefits of INOpulse WARREN, N.J., November 7, 2019 - Bellerophon Therapeutics, Inc. (Nasdaq: |
|
| November 6, 2019 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 6, 2019 Bellerophon Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-36845 47-3116175 (State or Other Jurisdiction of Incorporation) (Commis |
|
| November 6, 2019 |
Bellerophon Provides Business Update and Reports Third Quarter 2019 Financial Results Exhibit 99.1 Bellerophon Provides Business Update and Reports Third Quarter 2019 Financial Results WARREN, N.J., November 6, 2019 - Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company, today provided a business update and reported financial results for the three and nine months ended September 30, 2019. “We are encouraged by the |
|
| November 6, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ý QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2019 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-36845 Beller |
|
| October 23, 2019 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): October 23, 2019 Bellerophon Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-36845 47-3116175 (State or Other Jurisdiction of Incorporation) (Commis |
|
| October 23, 2019 |
Exhibit 99.1 Bellerophon Presents New Positive Data from Cohort 1 of Ongoing Phase 2/3 Study of INOpulse® for Treatment of Pulmonary Hypertension Associated with Interstitial Lung Disease at CHEST 2019 Annual Meeting Results Presented in Late-Breaking Abstract as an Oral Presentation Presentation Will Also be Published in the Highlights from CHEST Special Edition WARREN, N.J., October 23, 2019 - B |
|
| September 16, 2019 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): September 16, 2019 Bellerophon Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-36845 47-3116175 (State or Other Jurisdiction of Incorporation) (Comm |
|
| September 16, 2019 |
Bellerophon Receives Orphan Drug Designation for Nitric Oxide in the Treatment of Idiopathic Pulmonary Fibrosis WARREN, N. |
|
| September 3, 2019 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 28, 2019 BELLEROPHON THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36845 47-3116175 (state or other jurisdiction of incorporation) (Com |
|
| August 8, 2019 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 8, 2019 Bellerophon Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-36845 47-3116175 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| August 8, 2019 |
Bellerophon Provides Business Update and Reports Second Quarter 2019 Financial Results Exhibit 99.1 Bellerophon Provides Business Update and Reports Second Quarter 2019 Financial Results WARREN, N.J., August 8, 2019 - Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company, today provided a business update and reported financial results for the three and six months ended June 30, 2019. “In the first half of 2019, Belle |
|
| August 8, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ý QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2019 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-36845 Bellerophon |
|
| August 1, 2019 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 1, 2019 Bellerophon Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-36845 47-3116175 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| August 1, 2019 |
Bellerophon Completes Enrollment in Cohort 2 of Ongoing Phase 2/3 Study of INOpulse® for Treatment of Pulmonary Hypertension Associated with Interstitial Lung Disease Initiation of Pivotal Cohort 3 Anticipated in Q1 2020 WARREN, N. |
|
| July 1, 2019 |
Exhibit 4.1 FORM OF AMENDMENT TO COMMON STOCK PURCHASE WARRANT This Amendment to Common Stock Purchase Warrant (this "Amendment"), dated as of June 28, 2019, is being entered into by and between Bellerophon Therapeutics, Inc., a Delaware corporation (the "Company"), and (the "Holder"). WHEREAS, the Holder is the record and beneficial owner of warrants (the "Existing Warrants") to purchase shares o |
|
| July 1, 2019 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 28, 2019 Bellerophon Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-36845 47-3116175 (State or Other Jurisdiction of Incorporation) (Commi |
|
| June 7, 2019 |
BLPH / Bellerophon Therapeutics, Inc. S-8 - - S-8 As filed with the Securities and Exchange Commission on June 7, 2019 Registration No. |
|
| May 21, 2019 |
Bellerophon Presents Additional Positive Data from Cohort 1 of Ongoing Phase 2/3 Study of INOpulse® for Treatment of Pulmonary Hypertension Associated with Interstitial Lung Disease at American Thoracic Society 115th International Conference Results Presented in Late-Breaking Abstract as an Oral Presentation WARREN, N. |
|
| May 21, 2019 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 21, 2019 Bellerophon Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-36845 47-3116175 (State or Other Jurisdiction of Incorporation) (Commission |
|
| May 14, 2019 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 14, 2019 Bellerophon Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-36845 47-3116175 (State or Other Jurisdiction of Incorporation) (Commission |
|
| May 9, 2019 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 9, 2019 Bellerophon Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-36845 47-3116175 (State or Other Jurisdiction of Incorporation) (Commission |
|
| May 9, 2019 |
Bellerophon Provides Business Update and Reports First Quarter 2019 Financial Results Exhibit 99.1 Bellerophon Provides Business Update and Reports First Quarter 2019 Financial Results WARREN, N.J., May 9, 2019 - Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company, today provided a business update and reported financial results for the first quarter ended March 31, 2019. “Bellerophon has achieved substantial progr |
|
| May 9, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ý QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2019 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-36845 Belleropho |
|
| April 8, 2019 |
Bellerophon Announces Agreement with FDA on Regulatory Approval Pathway for INOpulse® for Treatment of Pulmonary Hypertension Associated with Interstitial Lung Disease FDA Agrees to Primary Endpoint of Change in Moderate to Vigorous Physical Activity from Baseline to Week 16, Measured by Actigraphy FDA Also Agrees on Modification of Ongoing Phase 2b Study into a Phase 2/3 Trial, with Cohort 3 Serving as the Pivotal Phase 3 Study Completion of Cohort 2 and Initiation of Cohort 3 Expected in Second Half of 2019 Warren, NJ, April 8, 2019 - Bellerophon Therapeutics, Inc. |
|
| April 8, 2019 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): April 8, 2019 Bellerophon Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-36845 47-3116175 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| March 28, 2019 |
BLPH / Bellerophon Therapeutics, Inc. DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant [X] Filed by a Party other than the Registrant [ ] Check the appropriate box: [ ] Preliminary Proxy Statement [ ] Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) |
|
| March 28, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant [X] Filed by a Party other than the Registrant [ ] Check the appropriate box: [ ] Preliminary Proxy Statement [ ] Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) |
|
| March 14, 2019 |
BLPH / Bellerophon Therapeutics, Inc. S-8 As filed with the Securities and Exchange Commission on March 14, 2019 Registration No. |
|
| March 14, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2018 or ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-36845 Bellerophon The |
|
| March 8, 2019 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 7, 2019 BELLEROPHON THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36845 47-3116175 (state or other jurisdiction of incorporation) (Commi |
|
| March 1, 2019 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 27, 2019 BELLEROPHON THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36845 47-3116175 (state or other jurisdiction of incorporation) (C |
|
| February 14, 2019 |
EXHIBIT 99.1 JOINT FILING AGREEMENT The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement shall be filed on behalf of each of the undersigned without the necessity of filing additional joint filing agreements. The undersigned acknowledge that each shall be responsible for |
